(PSYCHIATRIC TIMES) - MedPage Today Action Points
ROCKVILLE, Md., Dec. 20 -- The FDA today approved Invega (paliperidone) for treatment of acute schizophrenia.
Although the drug contains an active substance never before approved by the FDA, that substance is an active metabolite of an old drug, the atypical antipsychotic Risperdal (risperidone), which is marketed for treating schizophrenia.
The effectiveness of Invega in the acute treatment of schizophrenia was established in three six-week placebo-controlled trials conducted in North America, Europe and Asia.
For full article, please visit: